XENETIC BIOSCIENCES

Xenetic Biosciences Reports DNase I Enhances CAR-T Cell Persistence and Survival in ASCO 2026 Data

- Xenetic Biosciences presented preclinical data at ASCO 2026 demonstrating that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. - The study showed DNase I degrades extracellular DNA and neutrophil extracellular traps that drive CAR-T cell exhaustion, improving CD8-positive T cell ratios and reducing exhaustion markers PD-1, LAG-3, and TIM-3. - In vivo studies using NALM-6 B cell leukemia and Raji Burkitt lymphoma models demonstrated improved tumor control, delayed relapse, and prolonged survival with DNase I combination therapy. - Translational observations from a pediatric patient with refractory Burkitt lymphoma showed marked CAR-T cell expansion and progressive tumor burden reduction following DNase I co-administration.